

Diagnosis and Management Approaches of Bronchiolitis in Infants, Systematic Review

¹Saad Mohammed Almaimouni, ²Rabea Mohammedtaher Qutub

Abstracts: We aimed with this study was to systematically review all presently available randomized trials on medical diagnosis and management therapies for the infants with bronchiolitis to determine whether approaches to therapies exist for the proper diagnosis. review of the literature included performing a thorough literature recognition and screening procedure, abstracting appropriate info from the qualified studies, by browsing PubMed to October 2016 utilizing the terms bronchiolitis AND diagnosis and treatment for all publications in english language. The reason for a baby's disease can considerably impact the requirement for extra workup; examples consist of babies below 2 months with fever and indications of lower breathing system disease. Total blood cell counts and chest x-rays can be beneficial in patients with uncommon medical courses or serious disease. In the majority of babies with bronchiolitis, the restricted proof readily available does not support regular usage of RSV screening, chest x-ray, or CBC counts.

Keywords: Bronchiolitis in infants, systematically review, literature recognition.

1. INTRODUCTION

Bronchiolitis is the most common lower breathing system infection in infants. Almost all kids have in fact been exposed to Respiratory Syncytial Virus (RSV), the factor for most of bronchiolitis cases, by their 2nd birthday. As much as 3% of all kids are hospitalized with bronchiolitis in their first year of life ⁽¹⁾. The diagnosis of bronchiolitis is based primarily on typical history and results of a health assessment ⁽²⁾. No matter the high incident of bronchiolitis, little arrangement exists on the perfect management of the disease ⁽³⁾. Among previously healthy children and kids who are hospitalized with bronchiolitis, 10-15% requirement substantial care, and half of those admitted to the comprehensive care system (ICU) will develop breathing failure requiring mechanical ventilatory help ⁽⁴⁾. Infants and kids with hereditary cardiovascular disease, relentless lung disease, or immunocompromise are at high hazard for severe disease, and the rate of ICU admission in this population may be as high as 31- 36%, and 11- 19% can be prepared for to require mechanical ventilation (4). The death attributable to RSV bronchiolitis is <1% in all hospitalized children, nevertheless it may be as high as 3.5% in high-risk children ⁽⁴⁾. There is significant variation in utilizing valuable screening and treatment of bronchiolitis ^(5,6). Treatments for bronchiolitis can be categorized as specific or symptomatic. The simply acknowledged specific treatment is aerosolized ribavirin, an antiviral agent for bronchiolitis induced by RSV. Among the popular symptomatic treatments are bronchodilators and corticosteroids. Little contract exists about the best management methods for this common disease, and, for that reason, care varies considerably throughout settings and countries ^(5,7,8).

Etiology:

Serious bronchiolitis is mostly activated by viral infection, with RSV accounting for greater than 50% of cases. Other important viral causes include adenovirus, influenza infection, parainfluenza infection, human metapneumovirus, and rhinovirus. Mycoplasma pneumoniae may often be associated with bronchiolitis ^(9,10,11). RSV is incredibly transmittable, with a 98% attack rate for beginner infection throughout rises. This lowers to a 75% attack rate for 2nd infections ⁽⁹⁾. Transmission normally requires close contact, with direct exposure of the nasal mucosa or conjunctiva to infected secretions (**figure1**) ⁽¹⁰⁾. Well brought out contact privacy preventative steps work in limiting spread of the infection.

Reinfection with RSV over an individual's life time dominates; nonetheless, the initial infection is usually the most severe and the most likely to consist of the lower breathing system ⁽¹¹⁾. The 2nd infection can similarly be rather severe,

nevertheless after 2 RSV infections; the gotten resistance usually provides a significant reduction in the strength of 3rd and subsequent infections ⁽⁹⁾.




Figure1: RSV Proteins In Green And Cell Cilia In Red.

The objective of this study was to systematically review all presently available randomized trials on medical diagnosis and management therapies for the infants with bronchiolitis to determine whether approaches to therapies exist for the proper diagnosis.

2. METHODOLOGY

systematic review of the literature included performing a thorough literature recognition and screening procedure, abstracting appropriate info from the qualified studies, by browsing PubMed to October 2016 utilizing the terms bronchiolitis AND diagnosis and treatment for all publications in english language. Searching was carried out by various customers, individually. We took a look at the complete manuscript of each recovered short article, and we browsed the referral list of each. We got in touch with specialists in the field and browsed the individual files of the authors for possible randomized, managed trial (RCT) citations.

The following requirements were utilized to recognize research studies for addition in this evaluation:

- **Study Design:** RCT
- **Population:** pediatric patients
- **Intervention:** diagnostic approaches and any intervention for the treatment of bronchiolitis

All research studies not satisfying the above addition requirements were left out.

3. RESULTS AND DISCUSSION

A. Diagnostic approaches of Bronchiolitis in infants:

The methods for identifying RSV as the causative agent of bronchiolitis included viral cultures, quick antigen detection tests (eg, direct immunofluorescence assay and enzyme immunoassays), polymerase chain reaction, and measurements of convalescent and extreme antibody titers. Quick antigen detection tests for RSV were made use of most frequently ⁽²⁸⁾. In great deals of research study studies, private detectives performed viral cultures on cases with undesirable findings for RSV. Many companies require RSV screening of all infants admitted to the health care center; the thinking is to allow cohorting of patients to lower nosocomial infections. No direct proof from randomized, managed trials reveals that this method avoids nosocomial transmission of RSV in kids ⁽²⁸⁾.

VIROLOGICAL TESTS:

5 research studies ^(12,13,14,15,16) analyzed the precision of different virological tests for RSV and other causative infections. and demonstrated that many tests for RSV exist which their test attributes differ. The 2000 Red Book from the American

Academy of Pediatrics reports that the total level of sensitivity of the quick antigen detection tests differs from 80% to 90%⁽¹⁷⁾. Particular test makers likely have additional, unpublished details on their own assays, as they generally report test characteristics in the strategy insert items that accompany test sets. Our search strategy would not have in fact identified this unpublished info. In addition to having a look at test agreement, Ahluwalia et al⁽¹²⁾ compared 2 methods of specimen collection and revealed that viral culture, enzyme immunoassays, and direct immunofluorescence assays all yielded beneficial results frequently when performed on nasopharyngeal aspirates than when performed on nasopharyngeal swabs⁽¹²⁾.

EFFICACY OF CBC COUNTS IN BRONCHIOLITIS:

10 research studies gotten CBC depends on all patients⁽¹⁸⁻²⁷⁾. In the majority of these research studies, nevertheless, the CBC outcomes were not reported or utilized just to show that the treatment and control groups were comparable at standard. Saijo et al⁽¹⁹⁾ associated leukocyte counts in 120 RSV-positive babies with radiologically defined classifications of lung disease (ie, lobar pneumonia vs bronchopneumonia vs bronchiolitis). They discovered that a leukocyte count of higher than 15000/ μ L and a neutrophil count of higher than 10000/ μ L were most likely in kids with lobar pneumonia or bronchopneumonia than in kids with bronchiolitis. The 3 disease classifications were specified radiologically. None of the research studies reporting CBC information showed their energy in identifying bronchiolitis or assisting treatment.

B. Management approaches of Bronchiolitis:

We situated 10 RCTs of ribavirin for more serious RSV bronchiolitis^(22,29-37) and a long-lasting follow-up from 1 of these 10 research studies⁽³⁵⁾. The overall variety of patients in the primary research studies was 320, and the total quality was low, with half of the primary research studies ranked as bad or reasonable. 5 research studies^(30, 31,34, 36,37) reported on our primary results of interest, such as days of hospitalization, length of time that a kid needed more extensive encouraging interventions, and period of disease. 4 of these research studies^(31,34,36,37) discovered no substantial distinctions with ribavirin treatment compared to saline placebo. The research study⁽³⁶⁾ that did discover distinctions in period of mechanical ventilation and hospitalization preferring ribavirin utilized sterilized water in the placebo arm.

6 of 10 research studies^(22,30,32,33,34,37) reported products that we categorized as secondary results, such as scientific ratings and scientific signs. Distinctions preferring ribavirin were discovered for hours to enhancement in cough and crepitations however not for wheezing or enhanced feeding in 1 research study⁽²²⁾. Disease seriousness ratings were much better in the ribavirin group compared to the water placebo group on days 1 and 4 however not on days 2 and 3 of treatment in another research study⁽³²⁾. Another research study⁽³⁷⁾ discovered much better scientific ratings in the ribavirin group compared with the saline placebo group on day 3 however not on days 1 and 2 of treatment. 3 of the 6 research studies^(30,33,34) reporting secondary results did not discover considerable distinctions in between the groups. The long-lasting follow-up research study⁽³⁵⁾ discovered fewer children with higher than 2 episodes of wheezing throughout years 1 through 6 after ribavirin treatment however no considerable distinctions in incident of total breathing diseases or signs in those 6 years. Another study⁵⁴ determined results such as variety of episodes of reactive respiratory tract disease and lower and upper breathing disease in a 1-year follow-up duration after usage of ribavirin vs normal treatment and discovered less episodes of each in the ribavirin group. Aside from patient withdrawals in 2 research studies^(30,34) for breathing compromise, eyelid erythema was the only drug-specific unfavorable occasion reported in these research studies⁽²²⁾.

Bronchodilators:

A variety of small RCTs have actually examined the efficiency of albuterol in the treatment of intense bronchiolitis, with conflicting outcomes. A double-blind, placebo-controlled trial assessed the effectiveness of nebulized albuterol in the treatment of babies aged 0-24 months with wheezing⁽³⁹⁾. Twenty-five infants were randomized to get nebulized albuterol or saline placebo. The babies were evaluated after each treatment for wheeze, retractions score, breathing rate, heart rate, and pulse oximetry. In this research study, the authors had the ability to show considerable enhancement in the wheeze and oxygenation ratings of those babies that got albuterol, while no substantial distinction in the heart rate and breathing rate were kept in mind. These findings are supported by a Canadian double-blind, placebo-controlled trial that examined 40 babies in between 6 weeks and 24 months of age with a very first episode of wheezing and symptoms and signs of bronchiolitis⁽⁴⁰⁾. Improvements were shown in oxygenation and work of breathing after 2 dosages of albuterol. A criticism of both of these research studies is that the patients were not followed with time, and no impact was shown in enhanced resolution of signs or in length of stay (LOS). A number of other research studies have actually revealed opposite outcomes, recommending that albuterol provides no constant enhancement in patients with bronchiolitis.

One research study by Gadomski et al, ⁽⁴¹⁾ evaluated 88 infants with the first episode of wheezing in an emergency scenario department setting. The subjects were randomized to obtain 2 nebulized albuterol or nebulized placebo treatments 30 minutes apart or a single dose of oral albuterol or saline placebo. The investigators identified breathing rate, heart rate, clinical scores, oxygen saturations and level of wakefulness. No substantial distinction was shown amongst the 4 groups. Klassen et al ⁽⁴²⁾ showed a short-term enhancement in scientific ratings 30 minutes after a single albuterol treatment; nevertheless no distinction was shown 60 minutes after the treatment, there was no distinction in between the 2 groups when oxygenation was compared.

4. CONCLUSION

The reason for a baby's disease can considerably impact the requirement for extra workup; examples consist of babies below 2 months with fever and indications of lower breathing system disease. Total blood cell counts and chest x-rays can be beneficial in patients with uncommon medical courses or serious disease. In the majority of babies with bronchiolitis, the restricted proof readily available does not support regular usage of RSV screening, chest x-ray, or CBC counts. Provided the high occurrence of bronchiolitis, potential trials of helpful and diagnostic screening are practical and required. Treatments for bronchiolitis can be classified as symptomatic or particular. The just recognized particular treatment is aerosolized ribavirin, an antiviral representative for bronchiolitis triggered by RSV.

REFERENCES

- [1] Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. *AJDC*. 1986;140:543-546.
- [2] Orenstein DM. Bronchiolitis. In: Behrman RE, Kliegman R, Jenson HB, eds. *Nelson Textbook of Pediatrics*. 16th ed. Philadelphia, Pa: WB Saunders Co; 2000: 1285.
- [3] Meissner HC. Uncertainty in the management of viral lower respiratory tract disease. *Pediatrics*. 2001;108:1000-1003.
- [4] Navas L, Wang E, de Carvalho V, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children: Pediatric Investigators Collaborative Network on Infections in Canada. *J Pediatr*. 1992;121:348-354.
- [5] Wang EE, Law BJ, Boucher FD, et al. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. *J Pediatr*. 1996;129:390-395.
- [6] Mallory MD, Shay DK, Garrett J, Bordley WC. Bronchiolitis management preferences and the influence of pulse oximetry and respiratory rate on the decision to admit. *Pediatrics* [serial online]. 2003;111:e45-e51. Accessed June 1, 2003
- [7] Willson DF, Horn SD, Hendley JO, Smout R, Gassaway J. Effect of practice variation on resource utilization in infants hospitalized for viral lower respiratory illness. *Pediatrics*. 2001;108:851-855.
- [8] Cahill P, Finan E, Loftus BG. Management of bronchiolitis: current practices in Ireland. *Ir Med J*. 2002;95:167-169.
- [9] Henderson FW, Collier AM, Clyde WA, Jr, et al. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. *N Engl J Med*. 1979;300:530-4.
- [10] Hall CB, Douglas RG, Jr, Schnabel KC, et al. Infectivity of respiratory syncytial virus by various routes of inoculation. *Infect Immun*. 1981;33:779-83.
- [11] Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. *JAMA*. 1999;282:1440-6.
- [12] Ahluwalia G, Embree J, McNicol P, Law B, Hammond GW. Comparison of nasopharyngeal aspirate and nasopharyngeal swab specimens for respiratory syncytial virus diagnosis by cell culture, indirect immunofluorescence assay, and enzyme-linked immunosorbent assay. *J Clin Microbiol*. 1987;25:763-767.

- [13] Chattopadhyaya D, Chatterjee R, Anand VK, Kumari S, Patwari AK. Lower respiratory tract infection in hospitalized children due to respiratory syncytial (RS) virus during a suspected epidemic period of RS virus in Delhi. *J Trop Pediatr.* 1992; 38:68-73. 7
- [14] Eugene-Ruellan G, Freymuth F, Bahloul C, Badrane H, Vabret A, Tordo N. Detection of respiratory syncytial virus A and B and parainfluenzavirus 3 sequences in respiratory tracts of infants by a single PCR with primers targeted to the L-polymerase gene and differential hybridization. *J Clin Microbiol.* 1998;36:796-801.
- [15] Ong GM, Wyatt DE, O'Neill HJ, McCaughey C, Coyle PV. A comparison of nested polymerase chain reaction and immunofluorescence for the diagnosis of respiratory infections in children with bronchiolitis, and the implications for a cohorting strategy. *J Hosp Infect.* 2001;49:122-128.
- [16] Warner JL, Whitehurst NJ, Todd SJ, Shalaby H, Wall LV. Comparison of directigen RSV with viral isolation and direct immunofluorescence for the identification of respiratory syncytial virus. *J Clin Microbiol.* 1990;28:480-483.
- [17] American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, Ill: American Academy of Pediatrics; 2000:484.
- [18] Can D, Inan G, Yendur G, Oral R, Gunay I. Salbutamol or mist in acute bronchiolitis. *Acta Paediatr Jpn.* 1998;40:252-255.
- [19] Saijo M, Ishii T, Kokubo M, Muroto K, Takimoto M, Fujita K. White blood cell count, C-reactive protein and erythrocyte sedimentation rate in respiratory syncytial virus infection of the lower respiratory tract. *Acta Paediatr Jpn.* 1996;38: 596-600.
- [20] Rodriguez WJ, Kim HW, Brandt CD, et al. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. *Pediatr Infect Dis J.* 1987;6: 159-163
- [21] Taber LH, Knight V, Gilbert BE, et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. *Pediatrics.* 1983; 72:613-618.
- [22] Barry W, Cockburn F, Cornall R, Price JF, Sutherland G, Vardag A. Ribavirin aerosol for acute bronchiolitis. *Arch Dis Child.* 1986;61:593-597.
- [23] Chipps BE, Sullivan WF, Portnoy JM. Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus. *Pediatr Infect Dis J.* 1993;12:653- 658.
- [24] De Boeck K, Van der Aa N, Van Lierde S, Corbeel L, Eeckels R. Respiratory syncytial virus bronchiolitis: a double-blind dexamethasone efficacy study. *J Pediatr.* 1997;131:919-921.
- [25] Friis B, Andersen P, Brenoe E, et al. Antibiotic treatment of pneumonia and bronchiolitis: a prospective randomized study. *Arch Dis Child.* 1984;59:1038-1045.
- [26] Kjolhede CL, Chew FJ, Gadomski AM, Marroquin DP. Clinical trial of vitamin A as adjuvant treatment for lower respiratory tract infections. *J Pediatr.* 1995;126: 807-812.
- [27] Kong XT, Fang HT, Jiang GQ, Zhai SZ, O'Connell DL, Brewster DR. Treatment of acute bronchiolitis with Chinese herbs. *Arch Dis Child.* 1993;68:468-471. 48. Lozano JM, Wang E. Bronchiolitis. *Clin Evid.* June 2002;(7):272-282.
- [28] Lozano JM, Wang E. Bronchiolitis. *Clin Evid.* June 2002;(7):272-282.
- [29] Edell D, Khoshoo V, Ross G, Salter K. Early ribavirin treatment of bronchiolitis: effect on long-term respiratory morbidity. *Chest.* 2002;122:935-939.
- [30] Everard ML, Swarbrick A, Rigby AS, Milner AD. The effect of ribavirin to treat previously healthy infants admitted with acute bronchiolitis on acute and chronic respiratory morbidity. *Respir Med.* 2001;95:275-280.
- [31] Guerguerian AM, Gauthier M, Lebel MH, Farrell CA, Lacroix J. Ribavirin in ventilated respiratory syncytial virus bronchiolitis: a randomized, placebocontrolled trial. *Am J Respir Crit Care Med.* 1999;160:829-834.
- [32] Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection: a randomized double-blind study. *N Engl J Med.* 1983;308:1443-1447.

- [33] Janai HK, Stutman HR, Zaleska M, et al. Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis. *Pediatr Infect Dis J.* 1993;12:214-218.
- [34] Meert KL, Sarnaik AP, Gelmini MJ, Lieh-Lai MW. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial. *Crit Care Med.* 1994; 22:566-572.
- [35] Rodriguez WJ, Kim HW, Brandt CD, et al. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. *Pediatr Infect Dis J.* 1987;6: 159-163.
- [36] Smith DW, Frankel LR, Mathers LH, Tang AT, Ariagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. *N Engl J Med.* 1991;325:24-29.
- [37] Taber LH, Knight V, Gilbert BE, et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. *Pediatrics.* 1983; 72:613-618.
- [38] Moler FW, Bandy KP, Custer JR. Ribavirin therapy for acute bronchiolitis: need for appropriate controls [letter]. *J Pediatr.* 1991;119:509-510.
- [39] Schweich PJ, Hurt TL, Walkley EI, et al. The use of nebulized albuterol in wheezing infants. *Pediatr Emerg Care.* 1992;8:184-8.
- [40] Schuh S, Canny G, Reisman JJ, et al. Nebulized albuterol in acute bronchiolitis. *J Pediatr.*1990;117:633-7.
- [41] Gadomski AM, Lichenstein R, Horton L, et al. Efficacy of albuterol in the management of bronchiolitis. *Pediatrics.* 1994; 93:907-12.
- [42] Klassen TP, Rowe PC, Sutcliffe T, et al. Randomized trial of salbutamol in acute bronchiolitis. *J Pediatr.* 1991; 118:807-11.